gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Oncology · 2017–2017
1decision
1medicine
1carried consumer input
98individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lanreotide Treatment of non-functional gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with unresectable locally advanced or metastatic disease (WHO… | Jul 2017 | Not recommended | 98 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.